Payment overview · 2025
General Payments
$2,107.00
84 reported records · 15 companies
Healthcare provider profile · identity verified
Rajiv Pasricha
Allopathic & Osteopathic Physicians|Family Medicine · NORTH BABYLON, NY · NPI 1023672953
Verified facts
What the public records show
CMS Open Payments records show Rajiv Pasricha received $2,107.00 in general payments during 2025 across 84 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARANESP as an associated drug or biological on 16 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Aranesp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $634.19 | 30.1% | 23 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $208.54 | 9.9% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $206.74 | 9.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.67 | 9.1% | 6 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $166.01 | 7.9% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $161.61 | 7.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.32 | 5.3% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $109.70 | 5.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.30 | 4.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.82 | 4.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.96 | 1.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.09 | 1.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.58 | 1.2% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $23.30 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.17 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,107.00 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $302.23 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $287.04 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $208.54 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $206.74 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $190.67 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $161.61 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $112.81 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $109.70 | 5 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $98.92 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.30 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.30 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $87.51 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $86.82 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $81.75 | 7 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $67.09 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.09 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 199 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 105 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 126 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ARANESP open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 13 recipient NPIs · example record 1227128438 |
Aranesp · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
126 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 84 |
| Gabapentin | Gabapentin | 310 | 78 |
| Furosemide | Furosemide | 281 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 69 |
| Sertraline Hcl | Sertraline Hcl | 205 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 52 |
| Eliquis | Apixaban | 199 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 61 |
| Mirtazapine | Mirtazapine | 176 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 40 |
| Losartan Potassium | Losartan Potassium | 148 | 41 |
| Alprazolam | Alprazolam | 140 | 39 |
| Potassium Chloride | Potassium Chloride | 137 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 37 |
| Metformin Hcl | Metformin Hcl | 129 | 45 |
| Mounjaro | Tirzepatide | 126 | 22 |
| Warfarin Sodium | Warfarin Sodium | 123 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 105 | 22 |
| Donepezil Hcl | Donepezil Hcl | 100 | 23 |
| Famotidine | Famotidine | 97 | 31 |
| Generlac | Lactulose | 90 | 11 |
| Valsartan | Valsartan | 87 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 26 |
| Trazodone Hcl | Trazodone Hcl | 79 | 23 |
| Entresto | Sacubitril/Valsartan | 78 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 14 |
| Carvedilol | Carvedilol | 72 | 21 |
| Lisinopril | Lisinopril | 69 | 28 |
| Levetiracetam | Levetiracetam | 68 | 14 |
| Montelukast Sodium | Montelukast Sodium | 68 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 12 |
| Tramadol Hcl | Tramadol Hcl | 60 | 25 |
| Allopurinol | Allopurinol | 59 | 18 |
| Risperidone | Risperidone | 59 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 20 |
| Torsemide | Torsemide | 54 | 14 |
| Admelog | Insulin Lispro | 52 | 11 |
| Spironolactone | Spironolactone | 52 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 36 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Prednisone | Prednisone | 47 | 42 |
| Xarelto | Rivaroxaban | 47 | 11 |
| Finasteride | Finasteride | 45 | 18 |
| Midodrine Hcl | Midodrine Hcl | 45 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 13 |
| Omeprazole | Omeprazole | 44 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Ozempic | Semaglutide | 43 | 19 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 23 |
| Enoxaparin Sodium | Enoxaparin Sodium | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | 18 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 25 |
| Cephalexin | Cephalexin | 33 | 24 |
| Glimepiride | Glimepiride | 33 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | 18 |
| Ramipril | Ramipril | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | 14 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Insulin Lispro | Insulin Lispro | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 11 |
| Tradjenta | Linagliptin | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 15 |
| Meloxicam | Meloxicam | 26 | 17 |
| Scopolamine | Scopolamine | 26 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 14 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Folic Acid | Folic Acid | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Azithromycin | Azithromycin | 21 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Mesalamine Er | Mesalamine | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | 13 |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | 11 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 15 | 13 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 14 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 15 | 13 |
| Lumigan | Bimatoprost | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,107.00 · 84 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KEVEYIS, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, UBRELVY, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error